Back to results
US 2021/0333266 A1Published application
Rapid quantitative assay to measure cftr function in a primary intestinal culture model
AssigneesUMC Utrecht Holding B.V., Koninklijke Nederlandse Akademie van Wetenschappen
InventorsJeffrey Matthijn Beekman, Johanna Florentia Dekkers, Cornelis Korstiaan Van Der Ent, Johannes Carolus Clevers
Life of this patent
Estimating the term…
Abstract
The invention relates to an assay for diagnosing a disease or affliction that affects fluid uptake or secretion or for studying the effectiveness of one or more drugs for treating the disease or affliction, wherein the assay comprises measuring swelling of one or more organoids.
Claims13
1-27. (canceled)
An in vitro method for diagnosing polycystic kidney disease, wherein the method comprises
- measuring swelling of one or more organoids generated from primary cells,
- wherein swelling means an increase in size of the one or more organoids due to fluid uptake,
- wherein the swelling is cystic fibrosis transmembrane receptor (CFTR) dependent, and
- wherein a larger size of said one or more organoids compared to a control organoid indicates the presence of polycystic kidney disease.
1 more element
An in vitro method for diagnosing polycystic kidney disease, wherein the method comprises
- stimulating one or more organoids, generated from primary cells derived from a patient, with a compound that targets the cystic fibrosis transmembrane receptor (CFTR),
- measuring a change in size of said one or more organoids, wherein said change in size is CFTR-dependent, and
- wherein an increase in size of said one or more organoids compared to a control organoid indicates the presence of polycystic kidney disease.
Dependencies are inferred from the claim text.